Name: Jasmina Brooks
New title: President, Biosense Webster
Previous title: VP, Global Strategic Marketing, Biosense Webster
Biosense Webster, a subsidiary of Johnson & Johnson that makes devices for diagnosing and treating heart arrhythmias, has promoted Jasmina Brooks to the role of president.
J&J bought Biosense in 1997, shortly before it launched the world’s first irrigated ablation catheter, and promptly combined it with its Cordis Webster company. The resulting business, Biosense Webster, has become a leading supplier of cardiac ablation technology, but now faces a changing market as it and rivals such as Boston Scientific advance pulsed field ablation devices that may improve on existing radiofrequency-based approaches.
Brooks has spent the past nine years at Biosense Webster, joining the business as director of global strategic marketing in 2014 and going on to secure multiple promotions. Before joining the company, Brooks spent 14 years at GE HealthCare. Celine Martin, company group chairman, cardiovascular and specialty solutions group for J&J, cited Brooks’ years of experience in electrophysiology as a strength that informed the appointment.
“Jass Brooks is a well-respected, collaborative leader with a deep knowledge of the electrophysiology space, a track record of successfully driving growth and market leadership, as well as a deep commitment to developing talent and fostering a culture of collaboration and inclusivity,” Martin said in a statement.
Brooks is taking over a business that reported growth in electrophysiology in the first quarter in all regions except Asia-Pacific, where volume-based procurement in China dragged on the results. Last year, J&J’s interventional solutions business, which houses the electrophysiology devices, grew sales 8.3% to $4.3 billion.
J&J promoted Brooks to replace Michael Bodner, who recently took up the role of global head of heart recovery for Johnson & Johnson MedTech after spending about a year leading Biosense Webster.